{"id":"NCT01698320","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","briefTitle":"Safety Study of Albuterol Spiromax® in Subjects With Asthma","officialTitle":"A Multi-Center 52-Week Study to Assess the Safety of Albuterol Spiromax® in Subjects With Asthma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-10","primaryCompletion":"2013-12","completion":"2013-12","firstPosted":"2012-10-03","resultsPosted":"2015-08-19","lastUpdate":"2015-08-19"},"enrollment":364,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Asthma"],"interventions":[{"type":"DRUG","name":"Placebo MDPI","otherNames":["placebo"]},{"type":"DRUG","name":"Albuterol MDPI","otherNames":["ProAir® RespiClick","Albuterol Spiromax"]}],"arms":[{"label":"Placebo MDPI-Albuterol MDPI","type":"PLACEBO_COMPARATOR"},{"label":"Albuterol MDPI-Albuterol MDPI","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the safety of Albuterol Spiromax® over 52 weeks during two dosing periods: (1) a 12-week, double-blind, placebo-controlled QID dosing period followed by (2) a 40-week, open-label PRN dosing period, and to evaluate Albuterol Spiromax® device performance through the life of the device during the study.","primaryOutcome":{"measure":"Participants With Adverse Experiences During Weeks 0-12 (Double-Blind Period)","timeFrame":"Day 1 to Week 12","effectByArm":[{"arm":"Placebo MDPI-Albuterol MDPI","deltaMin":105,"sd":null},{"arm":"Albuterol MDPI-Albuterol MDPI","deltaMin":84,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":15},"locations":{"siteCount":30,"countries":["United States"]},"refs":{"pmids":["26369589"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":168},"commonTop":["Upper respiratory tract infection","Nasopharyngitis","Sinusitis","Cough","Headache"]}}